Holly Brunton
Research Associate, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences
University of Glasgow, United Kingdom
Holly Brunton is currently a Research Associate in the laboratory of Professor Andrew Biankin at the Wolfson Wohl Cancer Research Centre, which is part of the Institute of Cancer Sciences at the University of Glasgow. Primary research efforts are focused towards advancing genotype guided stratified therapy for pancreatic cancer. Holly completed her doctorate in Biochemistry at the University of Sussex in 2011, studying DNA double strand break repair in the context of higher order chromatin structure. Holly joined the National Institute of Radiological Sciences, Japan, in 2011 as a Research Associate analyzing the effect of heavy-ion radiation on cell cycle arrest. In 2012, Holly moved to Manchester to work within the Molecular Cancer Studies department at the University of Manchester. Here, she investigated mechanisms of resistance to targeted cancer therapy in melanoma.
Cancer Biology
Oncology
Targeted cancer therapy
Personalised medicine
DNA damage
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report